Raymond James Financial Inc Adaptimmune Therapeutics PLC Transaction History
Raymond James Financial Inc
- $264 Billion
- Q4 2024
A detailed history of Raymond James Financial Inc transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Raymond James Financial Inc holds 31,081 shares of ADAP stock, worth $18,026. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,081Holding current value
$18,026% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ADAP
# of Institutions
84Shares Held
145MCall Options Held
60.8KPut Options Held
5.8K-
Matrix Capital Management Company, LP Waltham, MA37.7MShares$21.9 Million1.71% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$15.9 Million1.13% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$9.91 Million1.24% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR13.3MShares$7.71 Million0.46% of portfolio
-
Baillie Gifford & CO11.8MShares$6.86 Million0.01% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $94.8M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...